Latest News

Emmaus Medical’s New Drug Application for Sickle Cell Disease Recommended for Approval by FDA

Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that the overall benefit-risk profile of disease was favorable. MMS Holdings Inc. (MMS) has been providing clinical data, writing and regulatory submission support for Emmaus since 2015.

“MMS is so pleased to hear the outcome of the May 24th Advisory Committee meeting where the committee recommended the approval of Endari™, Emmaus’ treatment of SCD,” commented Uma Sharma, PhD, Chief Scientific Officer at MMS.

Dr. Sharma added, “We have been working with Emmaus for several years and it is clear the company brings a passion to this research. We are equally excited that we may soon see a new treatment for those with sickle cell disease and the first of its kind for pediatric patients. MMS looks forward to continuing to support Emmaus and the FDA through this review period.”

About MMS Holdings Inc.
MMS is a global clinical research organization that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex regulatory submission challenges. Our strong industry experience and data-driven approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards.

About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company’s research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com.

Suggested For You

news

May 23rd, 2019

Dr. Mike Poole Joins the Board of Scientific Advisors at Top Global CRO MMS Holdings

news

November 8th, 2018

Vivozon’s Non-Opioid Pain Killer has been granted the FDA’s Fast Track Designation through Regulatory Strategy Support from MMS

news

March 6th, 2024

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

June 27th, 2022

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration Between MAPS PBC and MMS Holdings

news

December 8th, 2021

MMS Holdings Wins 2021 Scrip Award for Best Contract Research Organization

news

August 12th, 2021

Pro-Bono Ultra-rare Disease Regulatory Assistance Program Created By MMS for Patient Advocacy Groups

news

August 28th, 2020

MichBio Invites MMS Founder and Chief Scientific Officer Dr. Uma Sharma to Join Board of Directors

news

May 5th, 2020

Green Valley Pharmaceutical And MMS Holdings Collaborate to Gain FDA Approval To Begin Clinical Trial For The First Alzheimer's Drug In 17 Years

news

March 20th, 2020

MMS Announces One Million Dollar Award For Pharmaceutical Companies Developing A Vaccine For COVID-19

news

March 13th, 2019

GHP Recognises MMS Holdings in the 2019 Biotechnology Awards Winners

news

October 11th, 2018

MMS Submission Support for Paratek Pharmaceuticals Garners FDA Approval